Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (1): 70-76.doi: 10.12092/j.issn.1009-2501.2022.01.010

Previous Articles     Next Articles

Bioequivalence study of buthlphthalide injection in Chinese healthy volunteers

CAI Mingmin1,2, SHAO Jing3, TANG Lu2, SUN Qiuyue2, DOU Ting2, QIAN Wei2, WANG Huiping1,2   

  1. 1 Drug Clinical Trial Institution, Zhongda Hospital, Southeast University, Nanjing 210009, Jiangsu, China
  • Received:2021-11-17 Revised:2021-12-25 Online:2022-01-26 Published:2022-02-09

Abstract: AIM: To establish a method to investigate pharmacokinetics and bioequivalence of buthlphthalide injection. METHODS: An open, randomized, and two-cycle crossover study was conducted in 24 healthy volunteers. Plasma concentrations of buthlphthalide were determined by LC-MS/MS after administering a single dose of reference drug or test drug. Main pharmacokinetic parameters were calculated by Phoenix WinNonlin 6.4 software. RESULTS: For the test drug and the reference drug, the main pharmacokinetic parameters of flurbiprofen were as follows: AUC0-t was (541.0±78.6) ng·mL-1·h and (525.0±76.1) ng·mL-1·h, AUC0-∞ was (571.0±82.1) ng·mL-1·h and (555.0±88.1) ng·mL-1·h, Cmax was (295.0±62.7) ng/mL and (291.0±56.5) ng/mL, and the median of Tmax was 0.92 (0.33, 0.92) h and 0.92 (0.33, 0.93) h, respectively. Under two kinds of conditions, 90%CIs of AUC0-t, AUC0-∞ and Cmax of the test preparation were 80%-125% of the corresponding parameters of the reference preparation,and there was no statistical significance in Tmax between the two preparations (P>0.05).CONCLUSION: The test drug and the reference drug are bioequivalent.

Key words: buthlphthalide injection, HPLC-MS/MS, bioequivalence

CLC Number: